Skip to main content
SpringerLink
Log in

Pneumocystosis

  • Chapter
  • First Online:
Essentials of Clinical Mycology

Abstract

Although considered an organism of low virulence, Pneumocystis jiroveci is an important cause of pneumonia in immunocompromised hosts, especially those with hematologic malignancies, organ transplants, HIV infection, certain congenital immunodeficiencies, and those receiving potent immunosuppressive drugs [1–8]. As the population of immunosuppressed patients has grown, and as our ability to detect organisms in respiratory specimens has improved, more and more cases have been recognized in the period 1970–2000 [1–3]. Pneumocystis infections continue to cause morbidity and mortality among susceptible patients who do not receive chemoprophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30 Suppl 1:S5–14.

    PubMed  Google Scholar 

  2. Thomas Jr CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–98.

    CAS  PubMed  Google Scholar 

  3. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections–going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48:609–11.

    PubMed  Google Scholar 

  4. Cailliez JC, Seguy N, Denis CM, et al. Pneumocystis carinii: an atypical fungal micro-organism. J Med Vet Mycol. 1996;34:227–39.

    CAS  PubMed  Google Scholar 

  5. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334:519–22.

    CAS  PubMed  Google Scholar 

  6. Stringer SL, Hudson K, Blase MA, Walzer PD, Cushion MT, Stringer JR. Sequence from ribosomal RNA of Pneumocystis carinii compared to those of four fungi suggests an ascomycetous affinity. J Protozool. 1989;36:14S–6S.

    CAS  PubMed  Google Scholar 

  7. Barton E, Campbell WGJ. Pneumocystis carinii in lungs of rats treated with cortisone acetate: Ultrastructural observations relating to the life cycle. Am J Pathol. 1969;54:209–36.

    PubMed  Google Scholar 

  8. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419–26.

    CAS  PubMed  Google Scholar 

  9. Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi DV. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci USA. 1989;86:8625–9.

    CAS  PubMed  Google Scholar 

  10. Volpe F, Ballantine SP, Delves CJ. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase. Eur J Biochem. 1993;216:449–58.

    CAS  PubMed  Google Scholar 

  11. Basselin M, Hunt SM, Abdala-Valencia H, Kaneshiro ES. Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone. Eukaryot Cell. 2005;4:1483–92.

    CAS  PubMed  Google Scholar 

  12. Huang L, Crothers K, Atzori C, et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10:1721–8.

    CAS  PubMed  Google Scholar 

  13. Iliades P, Meshnick SR, Macreadie IG. Mutations in the Pneumocystis jiroveci DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother. 2005;49:741–8.

    CAS  PubMed  Google Scholar 

  14. Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL. Molecular basis for atovaquone resistance in Pneumocystis jiroveci modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. J Biol Chem. 2004;279:2817–24.

    CAS  PubMed  Google Scholar 

  15. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jiroveci dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48:4301–5.

    CAS  PubMed  Google Scholar 

  16. Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jiroveci pneumonia. Emerg Infect Dis. 2004;10:1760–5.

    CAS  PubMed  Google Scholar 

  17. Gigliotti F. Pneumocystis carinii: has the name really been changed? Clin Infect Dis. 2005;41:1752–5.

    PubMed  Google Scholar 

  18. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8:891–6.

    PubMed  Google Scholar 

  19. Kovacs JA, Halpern JL, Swan JC, Moss J, Parrillo JE, Masur H. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol. 1988;140:2023–31.

    CAS  PubMed  Google Scholar 

  20. Peglow SL, Smulian AG, Linke MJ, et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296–306.

    CAS  PubMed  Google Scholar 

  21. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35–41.

    CAS  PubMed  Google Scholar 

  22. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713–20.

    PubMed  Google Scholar 

  23. Spencer L, Ukwu M, Alexander T, et al. Epidemiology of Pneumocystis colonization in families. Clin Infect Dis. 2008;46:1237–40.

    PubMed  Google Scholar 

  24. Walzer PD, Djawe K, Levin L, et al. Long-term serologic responses to the Pneumocystis jiroveci major surface glycoprotein in HIV-positive individuals with and without P. jiroveci infection. J Infect Dis. 2009;199:1335–44.

    PubMed  Google Scholar 

  25. Davis JL, Welsh DA, Beard CB, et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax. 2008;63:329–34.

    CAS  PubMed  Google Scholar 

  26. Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr. 2004;24:227–35.

    PubMed  Google Scholar 

  27. Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis. 2003;36:70–8.

    PubMed  Google Scholar 

  28. Tudor-Williams G. HIV infection in children in developing countries. Trans R Soc Trop Med Hyg. 2000;94:3–4.

    CAS  PubMed  Google Scholar 

  29. Worodria W, Okot-Nwang M, Yoo SD, Aisu T. Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. Int J Tuberc Lung Dis. 2003;7:117–23.

    CAS  PubMed  Google Scholar 

  30. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis. 1982;145:842–8.

    CAS  PubMed  Google Scholar 

  31. Beard CB, Fox MR, Lawrence GG, et al. Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: epidemiological implications. J Infect Dis. 2005;192:1815–8.

    CAS  PubMed  Google Scholar 

  32. Huang L, Beard CB, Creasman J, et al. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis. 2000;182:1192–8.

    CAS  PubMed  Google Scholar 

  33. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis. 2000;182:551–7.

    CAS  PubMed  Google Scholar 

  34. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301:2578–85.

    CAS  PubMed  Google Scholar 

  35. Ripamonti C, Orenstein A, Kutty G, et al. Restriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jiroveci isolates. J Infect Dis. 2009;200:1616–22.

    CAS  PubMed  Google Scholar 

  36. Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, Wakefield AE. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. Q J Med. 1998;91:813–20.

    CAS  Google Scholar 

  37. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997;35:2745–7.

    CAS  PubMed  Google Scholar 

  38. Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis. 1995;172:595–8.

    CAS  PubMed  Google Scholar 

  39. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis. 2004;10:1766–73.

    PubMed  Google Scholar 

  40. Vargas SL, Ponce CA, Galvez P, et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J. 2007;26:81–3.

    PubMed  Google Scholar 

  41. Vargas SL, Ponce CA, Hughes WT, et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis. 1999;29:1489–93.

    CAS  PubMed  Google Scholar 

  42. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med. 2004;170:408–13.

    PubMed  Google Scholar 

  43. Morris A, Netravali M, Kling HM, et al. Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:e64–8.

    PubMed  Google Scholar 

  44. Browne MJ, Hubbard SM, Longo DL, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med. 1986;104:338–44.

    CAS  PubMed  Google Scholar 

  45. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135–42.

    CAS  PubMed  Google Scholar 

  46. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–9.

    CAS  PubMed  Google Scholar 

  47. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jiroveci pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139–40.

    CAS  PubMed  Google Scholar 

  48. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–12.

    CAS  PubMed  Google Scholar 

  49. Peters SG, Prakash UB. Pneumocystis carinii pneumonia. Review of 53 cases. Am J Med. 1987;82:73–8.

    CAS  PubMed  Google Scholar 

  50. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832–7.

    CAS  PubMed  Google Scholar 

  51. Sugimoto H, Uchida H, Akiyama N, et al. Improved survival of renal allograft recipients with Pneumocystis carinii pneumonia by early diagnosis and treatment. Transplant Proc. 1992;24:1556–8.

    CAS  PubMed  Google Scholar 

  52. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant. 1992;10:267–72.

    CAS  PubMed  Google Scholar 

  53. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004;4:42.

    PubMed  Google Scholar 

  54. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23:1186–8.

    CAS  PubMed  Google Scholar 

  55. Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect. 1992;7:114–21.

    CAS  PubMed  Google Scholar 

  56. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.

    CAS  PubMed  Google Scholar 

  57. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12:138–51.

    PubMed  Google Scholar 

  58. Roths JB, Sidman CL. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun. 1993;61:1641–9.

    CAS  PubMed  Google Scholar 

  59. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.

    CAS  PubMed  Google Scholar 

  60. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323:1451–7.

    CAS  PubMed  Google Scholar 

  61. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:223–31.

    CAS  PubMed  Google Scholar 

  62. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–5.

    CAS  PubMed  Google Scholar 

  63. Chu SY, Hanson DL, Ciesielski C, Ward JW. Prophylaxis against Pneumocystis carinii pneumonia at higher CD4+ T-cell counts. JAMA. 1995;273:848.

    CAS  PubMed  Google Scholar 

  64. Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001;183:1409–12.

    CAS  PubMed  Google Scholar 

  65. Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. 2000;182:611–5.

    CAS  PubMed  Google Scholar 

  66. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000;181:872–80.

    CAS  PubMed  Google Scholar 

  67. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130:570–7.

    CAS  PubMed  Google Scholar 

  68. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4  +  T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118:712–20.

    CAS  PubMed  Google Scholar 

  69. Engelberg LA, Lerner CW, Tapper ML. Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome. Am Rev Respir Dis. 1984;130:689–94.

    CAS  PubMed  Google Scholar 

  70. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974;80:83–93.

    CAS  PubMed  Google Scholar 

  71. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.

    CAS  PubMed  Google Scholar 

  72. Brenner M, Ognibene FP, Lack EE, et al. Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1987;136:1199–206.

    CAS  PubMed  Google Scholar 

  73. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987;91:323–7.

    CAS  PubMed  Google Scholar 

  74. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR. 1997;169:967–75.

    CAS  PubMed  Google Scholar 

  75. Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest. 1995;108:946–51.

    CAS  PubMed  Google Scholar 

  76. Sepkowitz KA, Telzak EE, Gold JW, et al. Pneumothorax in AIDS. Ann Intern Med. 1991;114:455–9.

    CAS  PubMed  Google Scholar 

  77. Raviglione MC. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis. 1990;12:1127–38.

    CAS  PubMed  Google Scholar 

  78. Telzak EE, Cote RJ, Gold JW, Campbell SW, Armstrong D. Extrapulmonary Pneumocystis carinii infections. Rev Infect Dis. 1990;12:380–6.

    CAS  PubMed  Google Scholar 

  79. Baughman R. Current methods in diagnosis. In: Walzer P, editor. Pneumocystis carinii pneumonia. New York: Marcel Dekker; 1994.

    Google Scholar 

  80. Meduri GU, Stover DE, Greeno RA, Nash T, Zaman MB. Bilateral bronchoalveolar lavage in the diagnosis of opportunistic pulmonary infections. Chest. 1991;100:1272–6.

    CAS  PubMed  Google Scholar 

  81. Bigby TD, Margolskee D, Curtis JL, et al. The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133:515–8.

    CAS  PubMed  Google Scholar 

  82. Kovacs JA, Halpern JL, Lundgren B, Swan JC, Parrillo JE, Masur H. Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis. 1989;159:60–70.

    CAS  PubMed  Google Scholar 

  83. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589–93.

    CAS  PubMed  Google Scholar 

  84. Ng VL, Virani NA, Chaisson RE, et al. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J Clin Microbiol. 1990;28:2228–33.

    CAS  PubMed  Google Scholar 

  85. Pitchenik AE, Ganjei P, Torres A, Evans DA, Rubin E, Baier H. Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133:226–9.

    CAS  PubMed  Google Scholar 

  86. Kirsch CM, Jensen WA, Kagawa FT, Azzi RL. Analysis of induced sputum for the diagnosis of recurrent Pneumocystis carinii pneumonia. Chest. 1992;102:1152–4.

    CAS  PubMed  Google Scholar 

  87. Gill VJ, Evans G, Stock F, Parrillo JE, Masur H, Kovacs JA. Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies. J Clin Microbiol. 1987;25:1837–40.

    CAS  PubMed  Google Scholar 

  88. Huang SN, Fischer SH, O’Shaughnessy E, Gill VJ, Masur H, Kovacs JA. Development of a PCR assay for diagnosis of Pneumocystis carinii pneumonia based on amplification of the multicopy major surface glycoprotein gene family. Diagn Microbiol Infect Dis. 1999;35:27–32.

    CAS  PubMed  Google Scholar 

  89. Wakefield AE, Pixley FJ, Banerji S, et al. Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA of rat and human origin. Mol Biochem Parasitol. 1990;43:69–76.

    CAS  PubMed  Google Scholar 

  90. Lipschik GY, Gill VJ, Lundgren JD, et al. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet. 1992;340:203–6.

    CAS  PubMed  Google Scholar 

  91. Lu JJ, Chen CH, Bartlett MS, Smith JW, Lee CH. Comparison of six different PCR methods for detection of Pneumocystis carinii. J Clin Microbiol. 1995;33:2785–8.

    CAS  PubMed  Google Scholar 

  92. Gupta R, Mirdha BR, Guleria R, et al. Diagnostic significance of nested polymerase chain reaction for sensitive detection of Pneumocystis jiroveci in respiratory clinical specimens. Diagn Microbiol Infect Dis. 2009;64:381–8.

    CAS  PubMed  Google Scholar 

  93. Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG, Lundgren JD, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol. 1998;36:2068–72.

    CAS  PubMed  Google Scholar 

  94. Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002;40:490–4.

    CAS  PubMed  Google Scholar 

  95. Fischer S, Gill VJ, Kovacs J, et al. The use of oral washes to diagnose Pneumocystis carinii pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system. J Infect Dis. 2001;184:1485–8.

    CAS  PubMed  Google Scholar 

  96. Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J Infect Dis. 2003;187:1844–8.

    PubMed  Google Scholar 

  97. Daly KR, Huang L, Morris A, et al. Antibody response to Pneumocystis jiroveci major surface glycoprotein. Emerg Infect Dis. 2006;12:1231–7.

    CAS  PubMed  Google Scholar 

  98. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson Jr AB, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet. 2003;361:1267–8.

    CAS  PubMed  Google Scholar 

  99. Wang P, Huang L, Davis JL, et al. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum S-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta. 2008;396:86–8.

    CAS  PubMed  Google Scholar 

  100. Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jiroveci colonization: a prospective study. BMC Infect Dis. 2009;9:47.

    PubMed  Google Scholar 

  101. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest. 2007;131:1173–80.

    CAS  PubMed  Google Scholar 

  102. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1–  >  3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49:1128–31.

    CAS  PubMed  Google Scholar 

  103. Del Bono V, Mularoni A, Furfaro E, et al. Clinical evaluation of a (1, 3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol. 2009;16:1524–6.

    PubMed  Google Scholar 

  104. Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-{beta}-D-glucan as a diagnostic tool for Pneumocystis jiroveci pneumonia in patients with HIV infection or hematological malignancy. J Clin Microbiol. 2009;47:3871–4.

    CAS  PubMed  Google Scholar 

  105. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988;109:280–7.

    CAS  PubMed  Google Scholar 

  106. Ruf B, Rohde I, Pohle HD. Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia. Eur J Clin Microbiol Infect Dis. 1991;10:207–10.

    CAS  PubMed  Google Scholar 

  107. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996;124:792–802.

    CAS  PubMed  Google Scholar 

  108. Toma E. Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS. Eur J Clin Microbiol Infect Dis. 1991;10:210–3.

    CAS  PubMed  Google Scholar 

  109. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207. quiz CE1-4.

    Google Scholar 

  110. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842–8.

    CAS  PubMed  Google Scholar 

  111. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992;327:1836–41.

    CAS  PubMed  Google Scholar 

  112. Conte Jr JE, Chernoff D, Feigal Jr DW, Joseph P, McDonald C, Golden JA. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990;113:203–9.

    PubMed  Google Scholar 

  113. Conte Jr JE, Hollander H, Golden JA. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study. Ann Intern Med. 1987;107:495–8.

    PubMed  Google Scholar 

  114. Leoung GS, Feigal Jr DW, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990;323:769–75.

    CAS  PubMed  Google Scholar 

  115. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323:776–82.

    CAS  PubMed  Google Scholar 

  116. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521–7.

    CAS  PubMed  Google Scholar 

  117. Mills J, Leoung G, Medina I, Hopewell PC, Hughes WT, Wofsy C. Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988;32:1057–60.

    CAS  PubMed  Google Scholar 

  118. Safrin S, Sattler FR, Lee BL, et al. Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1991;4:244–9.

    CAS  PubMed  Google Scholar 

  119. Leoung GS, Mills J, Hopewell PC, Hughes W, Wofsy C. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986;105:45–8.

    CAS  PubMed  Google Scholar 

  120. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:693–9.

    CAS  PubMed  Google Scholar 

  121. Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis. 1992;14:183–8.

    CAS  PubMed  Google Scholar 

  122. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med. 1994;121:174–80.

    CAS  PubMed  Google Scholar 

  123. Catterall JR, Potasman I, Remington JS. Pneumocystis carinii pneumonia in the patient with AIDS. Chest. 1985;88:758–62.

    CAS  PubMed  Google Scholar 

  124. Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis. 2006;25:52–4.

    CAS  PubMed  Google Scholar 

  125. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36:1445–57.

    CAS  PubMed  Google Scholar 

  126. Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis. 2006;43:e92–4.

    CAS  PubMed  Google Scholar 

  127. Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation. 2007;84:685–8.

    CAS  PubMed  Google Scholar 

  128. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444–50.

    CAS  PubMed  Google Scholar 

  129. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev. 2006;3:CD006150.

    CAS  PubMed  Google Scholar 

  130. Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670–2.

    CAS  PubMed  Google Scholar 

  131. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–24.

    CAS  PubMed  Google Scholar 

  132. Montaner JS, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study. Ann Intern Med. 1991;114:948–53.

    CAS  PubMed  Google Scholar 

  133. Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1992;152:2465–70.

    CAS  PubMed  Google Scholar 

  134. Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med. 1987;147:1413–7.

    CAS  PubMed  Google Scholar 

  135. Shelhamer JH, Ognibene FP, Macher AM, et al. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for Pneumocystis pneumonia. Am Rev Respir Dis. 1984;130:1161–5.

    CAS  PubMed  Google Scholar 

  136. Radhi S, Alexander T, Ukwu M, Saleh S, Morris A. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis. 2008;8:118.

    PubMed  Google Scholar 

  137. Morris A. Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jiroveci pneumonia over the course of the AIDS epidemic. Clin Infect Dis. 2008;46:634–6.

    PubMed  Google Scholar 

  138. Powell K, Davis JL, Morris AM, Chi A, Bensley MR, Huang L. Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest. 2009;135:11–7.

    PubMed  Google Scholar 

  139. Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med. 1984;101:1–7.

    CAS  PubMed  Google Scholar 

  140. Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med. 2002;3:207–11.

    CAS  PubMed  Google Scholar 

  141. Dean GL, Williams DI, Churchill DR, Fisher MJ. Transient clinical deterioration in HIV patients with Pneumocystis carinii pneumonia after starting highly active antiretroviral therapy: another case of immune restoration inflammatory syndrome. Am J Respir Crit Care Med. 2002;165(Dean GL, Williams DI, Churchill DR, Fisher MJ):1670. author reply.

    PubMed  Google Scholar 

  142. Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis. 2002;35:491–3.

    PubMed  Google Scholar 

  143. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418–27.

    CAS  PubMed  Google Scholar 

  144. Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2001;164:847–51.

    CAS  PubMed  Google Scholar 

  145. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4:e5575.

    PubMed  Google Scholar 

  146. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159–66.

    PubMed  Google Scholar 

  147. Gryzan S, Paradis IL, Zeevi A, et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival. Am Rev Respir Dis. 1988;137:1268–74.

    CAS  PubMed  Google Scholar 

  148. Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol. 1991;48:406–9.

    CAS  PubMed  Google Scholar 

  149. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med. 1992;327:1853–60.

    CAS  PubMed  Google Scholar 

  150. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17:770–82.

    PubMed  Google Scholar 

  151. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185–9.

    CAS  PubMed  Google Scholar 

  152. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44:453–5.

    CAS  PubMed  Google Scholar 

  153. Winston DJ. Prophylaxis and treatment of infection in the bone marrow transplant recipient. Curr Clin Topics Infect Dis. 1993;13:293–321.

    CAS  Google Scholar 

  154. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1–125, CE1-7.

    Google Scholar 

  155. De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36:879–83.

    PubMed  Google Scholar 

  156. Kovacs JA, Masur H. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992;14:1005–9.

    CAS  PubMed  Google Scholar 

  157. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58:1–166.

    PubMed  Google Scholar 

  158. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340:1301–6.

    CAS  PubMed  Google Scholar 

  159. Furrer H, Opravil M, Rossi M, et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS. 2001;15:501–7.

    CAS  PubMed  Google Scholar 

  160. Green H, Hay P, Dunn DT, McCormack S. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy. HIV Med. 2004;5:278–83.

    CAS  PubMed  Google Scholar 

  161. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS. 1999;13:1647–51.

    CAS  PubMed  Google Scholar 

  162. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001;344:168–74.

    CAS  PubMed  Google Scholar 

  163. de Quiros JC Lopez Bernaldo, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001;344:159–67.

    Google Scholar 

  164. D’Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count  <  200 cells/microl when viral replication is suppressed. AIDS. 2007;21:1711–5.

    PubMed  Google Scholar 

  165. Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993;328:1514–20.

    CAS  PubMed  Google Scholar 

  166. Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med. 1989;87:329–31.

    CAS  PubMed  Google Scholar 

  167. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177–88.

    CAS  PubMed  Google Scholar 

  168. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995;122:755–61.

    CAS  PubMed  Google Scholar 

  169. Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA. 1995;273:1197–202.

    CAS  PubMed  Google Scholar 

  170. El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis. 1999;29:775–83.

    CAS  PubMed  Google Scholar 

  171. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627–32.

    CAS  PubMed  Google Scholar 

  172. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992;117:106–11.

    CAS  PubMed  Google Scholar 

  173. Conte Jr JE, Upton RA, Phelps RT, Wofsy CB, Zurlinden E, Lin ET. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis. 1986;154:923–9.

    PubMed  Google Scholar 

  174. Murphy RL, Lavelle JP, Allan JD, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med. 1991;90:418–26.

    CAS  PubMed  Google Scholar 

  175. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med. 1990;323:1500–4.

    Google Scholar 

  176. Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med. 1995;122:658–63.

    CAS  PubMed  Google Scholar 

  177. Holtzer CD, Flaherty Jr JF, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998;18:831–5.

    CAS  PubMed  Google Scholar 

  178. Sangiolo D, Storer B, Nash R, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2005;11:521–9.

    CAS  PubMed  Google Scholar 

  179. Lavelle J, Falloon J, Morgan A, et al. Weekly dapsone and dapson/pyrimethamine for Pneumocystis pneumonia prophylaxis. In: VII International Conference on AIDS 1991;7:233. Florence; 1991.

    Google Scholar 

  180. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1995;20:531–41.

    CAS  PubMed  Google Scholar 

  181. Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis. 1999;180:369–76.

    CAS  PubMed  Google Scholar 

  182. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. 1998;339:1889–95.

    CAS  PubMed  Google Scholar 

  183. Kazanjian P, Locke AB, Hossler PA, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998;12:873–8.

    CAS  PubMed  Google Scholar 

  184. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet. 1998;351:1631–2.

    CAS  PubMed  Google Scholar 

  185. Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jiroveci dihydropteroate synthase gene mutations. AIDS. 2005;19:801–5.

    PubMed  Google Scholar 

  186. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999;354:1347–51.

    CAS  PubMed  Google Scholar 

  187. Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet. 2001;358:545–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Critical Care Medicine, National Institutes of Health, Bethesda, MD, USA

    Henry Masur

Authors
  1. Catherine F. Decker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry Masur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry Masur .

Editor information

Editors and Affiliations

  1. Veterans Affairs Ann Arbor Healthcare, Professor of Internal Medicine, University of Michigan Medical School, 2215 Fuller Road, Ann Arbor, 48105, Michigan, USA

    Carol A. Kauffman

  2. Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Blvd., Birmingham, 35294, Alabama, USA

    Peter G. Pappas

  3. Division of Infectious Diseases, Wayne State University School of Medicin, 3990 John R Street, Detroit, 48201, Michigan, USA

    Jack D. Sobel

  4. School of Medicine, Professor Emeritus of Medicine, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, 35294, Alabama, USA

    William E. Dismukes

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Decker, C.F., Masur, H. (2011). Pneumocystosis. In: Kauffman, C., Pappas, P., Sobel, J., Dismukes, W. (eds) Essentials of Clinical Mycology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6640-7_26

Download citation

Publish with us

Policies and ethics

Search

Navigation